Business Context and Reporting Period
This Form 8-K filing by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") covers the date of March 1, 2021. The report details a significant executive leadership transition within the company's finance department.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $350,000 per year for the new Chief Financial Officer.
- Target Bonus: Up to 50% of base salary.
- Stock Option Grant: 500,000 shares with an exercise price of $3.73 per share.
Material Changes
The primary material change reported is the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. He replaces Chris Sullivan, who served as Interim CFO since April 2020. Mr. Sullivan will remain with the company as the principal accounting officer. Mr. Greenway joins from Mesoblast Limited, bringing over 20 years of experience in investment banking and life sciences finance.
Outlook, Risks, and Unusual Items
Compensation Structure: The new CFO's employment agreement includes specific severance provisions. In the event of termination without "Cause" or for "Good Reason," Mr. Greenway is eligible for 12 months of continued base salary, a prorated bonus, and accelerated vesting of stock options equivalent to 12 additional months of service. He is also subject to one-year non-competition and non-solicitation covenants.
Regulatory Compliance: The stock option grant was approved as an inducement award under NASDAQ Listing Rule 5635(c)(4), as it was material to Mr. Greenway's decision to join the company.
Investor Verification Checklist
- Verify the correct registrant name is Cerecor Inc. (Ticker: CERC), not Avalo Therapeutics.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Stock Option Agreement (Exhibit 10.2) for detailed vesting schedules and termination definitions.
- Monitor future filings for the impact of the new CFO on capital markets initiatives and investor relations strategy.
- Confirm the vesting cliff date (first anniversary of March 1, 2021) for the 500,000 share option grant.